Sibrafiban

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994; 308: 81–106
Article Google Scholar
Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394–405
PubMed CAS Google Scholar
Cannon CP, McCabe CH, Borzak S, et al. for the TTMI 12 Investigators. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998; 97: 340–9
Article PubMed CAS Google Scholar
Kereiakes DJ, Cannon CP. Oral platelet glycoprotein IIb/IIIa blockade. In: Cannon CP, editor. Management of acute coronary syndromes. Totowa, (NJ): Humana Press. In press

Author information

Cardiovascular Division, Department of Medicine, Brigham, USA
Christopher P. Cannon
Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Christopher P. Cannon

Authors

Christopher P. Cannon
View author publications
You can also search for this author in PubMed Google Scholar

Cannon, C.P. Sibrafiban. Drugs 57, 231–232 (1999). https://doi.org/10.2165/00003495-199957020-00014

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.